anmelden
Novartis Aktie
132,38
EUR
-1,86
EUR
-1,39
%
132,40
EUR
-1,50
EUR
-1,12
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 247,88 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 27.03.23 | Novartis Buy | Jefferies & Company Inc. | |
| 14.03.23 | Novartis Sell | Deutsche Bank AG | |
| 17.02.23 | Novartis Sell | Deutsche Bank AG | |
| 13.02.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 07.02.23 | Novartis Sell | Deutsche Bank AG | |
| 06.02.23 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 03.02.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 02.02.23 | Novartis Underperform | Credit Suisse Group | |
|
Werbung
|
|||
| 02.02.23 | Novartis Sell | Deutsche Bank AG | |
| 01.02.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.02.23 | Novartis Buy | Jefferies & Company Inc. | |
| 01.02.23 | Novartis Neutral | UBS AG | |
| 25.01.23 | Novartis Underweight | Barclays Capital | |
| 24.01.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 09.01.23 | Novartis Neutral | UBS AG | |
| 06.01.23 | Novartis Underperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underweight | Morgan Stanley | |
| 05.01.23 | Novartis Buy | Jefferies & Company Inc. | |
| 03.01.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 23.12.22 | Novartis Underweight | Barclays Capital | |
| 14.12.22 | Novartis Neutral | UBS AG | |
| 12.12.22 | Novartis Buy | Jefferies & Company Inc. | |
| 09.12.22 | Novartis Sell | Deutsche Bank AG | |
| 08.12.22 | Novartis Market-Perform | Bernstein Research | |
| 08.12.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 07.12.22 | Novartis Sell | Deutsche Bank AG | |
| 06.12.22 | Novartis Neutral | UBS AG | |
| 22.11.22 | Novartis Sell | Deutsche Bank AG | |
| 27.10.22 | Novartis Sell | Deutsche Bank AG | |
| 26.10.22 | Novartis Market-Perform | Bernstein Research | |
| 26.10.22 | Novartis Underperform | Credit Suisse Group | |
| 26.10.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 26.10.22 | Novartis Underweight | Barclays Capital | |
| 25.10.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.10.22 | Novartis Sell | Deutsche Bank AG | |
| 25.10.22 | Novartis Neutral | UBS AG | |
| 25.10.22 | Novartis Buy | Jefferies & Company Inc. | |
| 24.10.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.10.22 | Novartis Underweight | Barclays Capital | |
| 07.10.22 | Novartis Sell | Deutsche Bank AG | |
| 05.10.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.09.22 | Novartis Neutral | UBS AG | |
| 23.09.22 | Novartis Sell | Deutsche Bank AG | |
| 23.09.22 | Novartis Underweight | Barclays Capital | |
| 23.09.22 | Novartis Underperform | Credit Suisse Group | |
| 23.09.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.09.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 21.09.22 | Novartis Sell | Deutsche Bank AG | |
| 16.09.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 15.09.22 | Novartis Underperform | Credit Suisse Group | |
Werbung
Werbung
